University of Kentucky

UKnowledge
Epidemiology and Environmental Health Faculty
Publications

Epidemiology and Environmental Health

9-28-2018

Barriers to Receipt of Prenatal Tetanus Toxoid, Reduced Diptheria
Toxoid, and Acellular Pertussis Vaccine Among Mothers of
Infants Aged < 4 Months with Pertussis — California, 2016
Sarah New
California Department of Public Health

Kathleen Winter
University of Kentucky, kathleen.winter@uky.edu

Kathleen Harriman
California Department of Public Health

Anya Gutman
California Department of Public Health

Amber Christiansen
California Department of Public Health
Follow this and additional works at: https://uknowledge.uky.edu/epidemiology_facpub
See next page for additional authors
Part of the Epidemiology Commons, and the Women's Health Commons

Right click to open a feedback form in a new tab to let us know how this document benefits you.
Repository Citation
New, Sarah; Winter, Kathleen; Harriman, Kathleen; Gutman, Anya; Christiansen, Amber; and Royce, Sarah,
"Barriers to Receipt of Prenatal Tetanus Toxoid, Reduced Diptheria Toxoid, and Acellular Pertussis
Vaccine Among Mothers of Infants Aged < 4 Months with Pertussis — California, 2016" (2018).
Epidemiology and Environmental Health Faculty Publications. 37.
https://uknowledge.uky.edu/epidemiology_facpub/37

This Article is brought to you for free and open access by the Epidemiology and Environmental Health at
UKnowledge. It has been accepted for inclusion in Epidemiology and Environmental Health Faculty Publications by
an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.

Barriers to Receipt of Prenatal Tetanus Toxoid, Reduced Diptheria Toxoid, and
Acellular Pertussis Vaccine Among Mothers of Infants Aged < 4 Months with
Pertussis — California, 2016
Digital Object Identifier (DOI)
https://doi.org/10.15585/mmwr.mm6738a6

Notes/Citation Information
Published in Morbidity and Mortality Weekly Report, v. 67, no. 38, p. 1068-1071.
This article was published by the U.S. Department of Health and Human Services/ Centers for Disease
Control and Prevention, and is in the public domain.

Authors
Sarah New, Kathleen Winter, Kathleen Harriman, Anya Gutman, Amber Christiansen, and Sarah Royce

This article is available at UKnowledge: https://uknowledge.uky.edu/epidemiology_facpub/37

Morbidity and Mortality Weekly Report

Barriers to Receipt of Prenatal Tetanus Toxoid, Reduced Diphtheria Toxoid, and
Acellular Pertussis Vaccine Among Mothers of Infants Aged <4 Months
with Pertussis — California, 2016
Sarah New, MPH1; Kathleen Winter, PhD1,2, Rebeca Boyte, MAS1; Kathleen Harriman, PhD1; Anya Gutman, MPH1;
Amber Christiansen, MPH1; Sarah Royce, MD1

Vaccination with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine is recommended
for all pregnant women to protect infants who are too young
for vaccination from severe pertussis-related outcomes (1–3).
However, Tdap vaccine coverage among pregnant women
remains suboptimal in California (4). California mothers
whose infants developed pertussis in 2016 and their prenatal
care providers were interviewed to ascertain possible reasons for
low Tdap vaccine coverage. Mothers who were offered Tdap
vaccination on-site during a routine prenatal visit were more
likely to be vaccinated than were mothers who were referred
off-site for vaccination. Mothers insured by Medicaid were
less likely to receive Tdap vaccine than were mothers with
private insurance, even when the vaccine was stocked on-site.
Nearly all vaccinated mothers received Tdap vaccine in their
prenatal clinic. Incorporating Tdap vaccination into routine
prenatal care visits is an effective means to increase prenatal
Tdap vaccination coverage.
Most severe and fatal cases of pertussis occur in infants who
have not yet started the primary pertussis vaccination series. To
reduce the incidence of pertussis in these young infants, the
Advisory Committee on Immunization Practices (ACIP) recommends that pregnant women receive Tdap vaccine at the earliest
opportunity, during 27–36 weeks’ gestation of each pregnancy
(3). Vaccination during this period results in optimal transplacental transfer of maternal pertussis antibodies, which provides
infants with passive protection against pertussis during the first
weeks of life (1–3). Despite this recommendation, prenatal Tdap
vaccine coverage in California remains low, with 52% of pregnant women estimated to have been vaccinated, and coverage
is even lower (40%) among women with Medicaid insurance
(5). In 2016, a low-incidence pertussis year in California, 114
pertussis cases, which included two pertussis-related deaths,
occurred among infants aged <4 months.
California local health department personnel completed a
case report form and attempted to complete a supplemental
questionnaire using information collected during routine case
investigation interviews with mothers of all 114 infants aged
<4 months with pertussis who had illness onset during 2016.
Interviewed mothers were asked to identify their prenatal care
provider; whether they received a recommendation for Tdap
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vaccination during pregnancy with the case infant; whether
they received Tdap vaccine; and if so, the date and location
it was administered. Mothers who reported that they did not
receive Tdap vaccine during pregnancy were asked why Tdap
vaccine was not administered. Prenatal care providers were
asked to identify the mothers’ insurance type during pregnancy; whether Tdap vaccination was recommended during
pregnancy; whether Tdap vaccine was stocked in the clinic;
and if not, why it was not stocked. Providers were also asked
to verify the mothers’ Tdap vaccination status, and if Tdap
vaccine was administered, the date and gestational week of
administration. If mothers were referred off-site for Tdap
vaccination, providers were asked whether they followed up
to ensure that Tdap vaccination occurred. In addition, the
California Immunization Registry was searched in an attempt
to identify doses of Tdap vaccine that were not reported during interviews. However, this registry was mandated in late
2016 for pharmacists only. Additional variables collected
from infant pertussis case reports included whether the infant
was hospitalized or admitted to an intensive care unit (ICU)
and the infant’s outcome. Relative risks and 95% confidence
intervals (CIs) were calculated to identify differences between
vaccinated and unvaccinated mothers and barriers to receipt
of prenatal Tdap vaccine. Because reporting of pertussis cases
in infants aged <4 months is mandated in California, the
follow-up interviews and data collected for this analysis were
considered to be nonresearch data.
Sixty-six (58%) mothers and their prenatal care providers
completed the supplemental questionnaire during routine case
investigations. Data on mother’s insurance status, stocking
status of Tdap vaccine by provider, or mother’s gestational
week of pregnancy (if vaccinated) were incomplete for six
(9%) mothers and were excluded from relevant calculations.
Twenty-six (39%) of the 66 interviewed mothers reported
receiving Tdap vaccine during their pregnancy with the case
infant; among these, 24 (92%) were vaccinated at their prenatal
care provider’s office. Prenatal care providers documented Tdap
vaccine administration for 25 of the 26 mothers who reported
vaccination; no information on a Tdap vaccine dose was found
in the medical record or the California Immunization Registry
for one mother. Among the 25 mothers with documentation
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of receipt of prenatal Tdap vaccine, 20 (80%) were vaccinated
according to ACIP recommendations, during 27–36 weeks’
gestation (median = 32 weeks). Five (20%) mothers received
Tdap vaccine outside the recommended 27–36 week time
frame (one each at 26, 38, and 39 weeks’ gestation and two
at 37 weeks). Among the 20 infants whose mothers were
vaccinated during the recommended time frame, four were
hospitalized, but none required admission to an ICU. Among
the five infants whose mothers were vaccinated outside the
recommended time frame, two were hospitalized, including
one who required ICU admission and subsequently died.
Among the 66 interviewed mothers, 40 (61%) did not
receive Tdap vaccine during pregnancy and among these
mothers, 20 (50%) of their infants were hospitalized, including
eight (40%) who were admitted to an ICU, one of whom died.
Among the 40 unvaccinated mothers, 10 (25%) did not receive
a recommendation or referral off-site for vaccination from
their prenatal care provider, nine (23%) were referred off-site
for vaccination but did not receive Tdap vaccine, eight (20%)
mothers reported refusing Tdap vaccine for personal reasons,
seven (18%) were deferred for vaccination by their provider
for a reason not considered by ACIP to be a contraindication
(prior receipt of Tdap vaccine, minor illness, or current medication use), three (8%) did not receive prenatal care during
27–36 weeks’ gestation, one (3%) reported a possible valid
contraindication (adverse reaction to pertussis vaccination
as a child), and no information was available for two (5%)
women (6) (Table 1). Sixteen (40%) of the 40 mothers who
were not vaccinated during pregnancy received Tdap vaccine
postpartum (the recommended strategy before 2011).
Among the 60 (91%) mothers with complete information,
19 (73%) of 26 women with private insurance and 15 (44%)
of 34 women insured by Medicaid received prenatal care from a
provider who stocked Tdap vaccine on-site (Table 2). Fourteen
(54%) mothers with private insurance received Tdap vaccine
on time, compared with six (18%) of mothers with Medicaid
TABLE 1. Reasons prenatal Tdap vaccination was not received during
pregnancy among interviewed mothers of infants aged <4 months
with pertussis (N = 40) — California, 2016
Reason

No. (%)

No recommendation or referral
Referred off-site, did not follow up
Refused for personal reasons
Invalid contraindication*
No prenatal care in third trimester
Valid contraindication
Unknown

10 (25)
9 (23)
8 (20)
7 (18)
3 (8)
1 (3)
2 (5)

Abbreviation: Tdap = tetanus toxoid, reduced diphtheria toxoid, and acellular
pertussis vaccine.
* Invalid contraindications included prior receipt of prenatal Tdap (two); minor
illness (two); previous illness associated with receipt of influenza vaccine (one);
family member up to date with pertussis vaccination (one); and current
medication use (one).

insurance. Mothers whose providers stocked Tdap vaccine
on-site were significantly more likely to have been vaccinated
(relative risk [RR] = 3.3; 95% CI = 1.9–5.5) than were mothers
whose providers did not stock Tdap vaccine. Mothers insured
by Medicaid were significantly less likely than those with private insurance to receive prenatal Tdap vaccine (0.4; 0.2–0.8)
or to receive prenatal Tdap vaccine during the appropriate
time frame, even when it was stocked on-site (0.5; 0.3–1.1).
Among the 61 interviewed prenatal care providers whose
Tdap vaccine stocking policies were known, 34 (56%) stocked
Tdap vaccine on-site. Among the 27 (44%) providers who
did not stock Tdap vaccine on-site, 17 (63%) recommended
Tdap vaccine during pregnancy, 16 of whom referred mothers
off-site for vaccination, typically to a pharmacy, local public
health department, or the mother’s primary care physician.
Two (13%) of the 16 mothers referred off-site were vaccinated,
including one who was vaccinated at 38 weeks’ gestation. In
only one case was the Tdap dose documented in the mother’s
medical record. Among the 27 providers who did not stock
Tdap vaccine on-site, the most common reasons cited for not
stocking were cost (44%) and reimbursement (41%) issues.
Discussion

In this review of 66 mothers of infants aged <4 months who
became ill with pertussis in 2016, 20 mothers (30%) received
Tdap vaccine during the time frame recommended by ACIP, all
of whom were vaccinated in their prenatal clinic during a routine visit. Mothers whose providers stocked Tdap on-site were
more likely to be vaccinated than were those whose providers
did not stock Tdap. This finding is consistent with a previous survey demonstrating that receipt of influenza vaccine by
pregnant women was more likely among those whose prenatal
TABLE 2. Prenatal Tdap vaccination outcomes for interviewed
mothers of infants aged <4 months with pertussis (N = 60*), by clinic
Tdap vaccine stocking policy and mothers’ insurance coverage —
California, 2016
Tdap vaccination status
no. (%)
Tdap policy/Insurance
coverage

Received per ACIP
recommendations†

Tdap stocked on-site in clinic (n = 34)
Private insurance (n = 19)
14 (41)
Medicaid (n = 15)
6 (18)
Tdap not stocked on-site in clinic (n = 26)
Private insurance (n = 7)
0 (—)
Medicaid (n = 19)
0 (—)
Unknown (n = 5)
0 (—)

Not received on
time or at all
5 (15)
9 (26)
7 (27)
19 (73)
5 (100)

Abbreviations: ACIP = Advisory Committee on Immunization Practices;
Tdap = tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis.
* Six of the 66 mothers interviewed were excluded because data on mother’s
insurance status, stocking status of Tdap vaccine by provider, or mothers’
gestational week of pregnancy (if vaccinated) were incomplete.
† Among clinics that stocked Tdap vaccine on-site, 20 mothers received Tdap
during 27–36 weeks’ gestation.
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care providers offered vaccination on-site (4). However, even
when prenatal care providers stocked Tdap vaccine on-site,
women insured by Medicaid were less likely to receive Tdap
vaccination than were women with private insurance. Previous
Tdap vaccination coverage estimates among pregnant women
in California were also lower among those insured by Medicaid
(40%) than among those with private insurance (65%) (5).
Reasons for this disparity are not known; however, a need exists
to reduce financial barriers to stocking and administering Tdap
vaccine in prenatal clinics, particularly among those serving
Medicaid patients.
To prevent pertussis among young infants, women should
receive Tdap vaccination during 27–36 weeks’ gestation during
every pregnancy. A recommendation by prenatal care providers for their pregnant patients to receive Tdap is important,
particularly among providers who do not stock Tdap vaccine
on-site. If Tdap vaccine is not stocked on-site, it is important
to provide pregnant patients with specific information* about
where they can receive Tdap vaccination and to follow up at
subsequent visits to ensure Tdap vaccine is received within
the recommended time frame (7,8). Approximately 40% of
the unvaccinated mothers in this analysis never received a
recommendation or referral for Tdap vaccine or were deferred
for reasons that were inconsistent with current ACIP recommendations, and 40% of the unvaccinated mothers, including
one who originally refused Tdap vaccination, received Tdap
vaccine postpartum, suggesting that prenatal-provider education about current Tdap vaccine recommendations is needed.
Eight (20%) of the 40 mothers who were not vaccinated during
pregnancy refused prenatal Tdap.
Fewer infants of mothers who were vaccinated according to
recommendations required hospitalization after developing
pertussis than did infants of unvaccinated mothers. Although
not statistically significant, this difference is consistent with a
previous report and highlights the importance of prenatal Tdap
vaccination in preventing severe outcomes of pertussis (9).
The findings in this report are subject to at least one limitation. The relatively small sample size might affect the generalizability of these findings to the U.S. population of pregnant
women and their prenatal care providers.
In California, pharmacists are permitted to provide immunizations, and all routinely recommended adult vaccines are
covered by Medicaid when given in a provider’s office or in
a pharmacy. Recent state regulations require pharmacists to
notify providers of immunizations administered and to enter
all doses into the California Immunization Registry, making
it possible for providers to know whether vaccine referrals to
* http://eziz.org/resources/pertussis-promo-materials/prenatal-tdap/.
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Summary
What is already known about this topic?
Although tetanus toxoid, reduced diphtheria toxoid, and acellular
pertussis (Tdap) vaccination is recommended for all pregnant
women during 27–36 weeks’ gestation to prevent infant
pertussis, coverage among pregnant women is suboptimal.
What is added by this report?
Among 66 interviewed mothers of infants aged <4 months with
pertussis, 30% appropriately received Tdap vaccine. Women
whose clinics stocked Tdap vaccine were more likely to be
vaccinated. Women with Medicaid were less likely to be
vaccinated than were those with private insurance, even when
treated in clinics that stocked Tdap vaccine.
What are the implications for public health practice?
Promoting on-site prenatal vaccination, educating providers
about Tdap recommendations, and strengthening off-site referral
likely will improve Tdap vaccination coverage during pregnancy.

pharmacies are successful. However, stocking vaccines on-site
in prenatal clinics is the best way to ensure that all pregnant
women are vaccinated and reduce the incidence of pertussis
among infants too young to be vaccinated.
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